S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.67 (+1.46%)
BABA   84.40 (+0.15%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-5.10%)
GE   104.10 (-1.61%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.67 (+1.46%)
BABA   84.40 (+0.15%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-5.10%)
GE   104.10 (-1.61%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.67 (+1.46%)
BABA   84.40 (+0.15%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-5.10%)
GE   104.10 (-1.61%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.67 (+1.46%)
BABA   84.40 (+0.15%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-5.10%)
GE   104.10 (-1.61%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:NVOS

Novo Integrated Sciences (NVOS) Stock Forecast, Price & News

$0.13
0.00 (-1.79%)
(As of 05:04 PM ET)
Compare
Today's Range
$0.13
▼
$0.13
50-Day Range
$0.11
▼
$0.20
52-Week Range
$0.10
▼
$2.14
Volume
1.83 million shs
Average Volume
21.12 million shs
Market Capitalization
$18.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

NVOS stock logo

About Novo Integrated Sciences (NASDAQ:NVOS) Stock

Novo Integrated Sciences, Inc. engages in the provision of medical services. The firm offers specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropodist, neurological functions, kinesiology, and dental services. Its multi-disciplinary healthcare services and protocols are directed at assessment, treatment, management, rehabilitation, and prevention through its clinics, affiliate clinics, retirement homes, and long-term facilities. The firm operates through the following business segments: healthcare services, and product manufacturing and development. The company was founded by Michael H. Rouse on November 27, 2000 and is headquartered in Bellevue, WA.

Receive NVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Integrated Sciences and its competitors with MarketBeat's FREE daily newsletter.

NVOS Stock News Headlines

May 26, 2023 | finance.yahoo.com
Novo Integrated Sciences Reports Fiscal Year 2023 Second Quarter Financial Results
May 26, 2023 | finance.yahoo.com
Novo Integrated Sciences First Quarter 2023 Earnings: US$0.12 loss per share (vs US$0.067 loss in 1Q 2022)
June 5, 2023 | Edge On The Street (Ad)
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
May 24, 2023 | seekingalpha.com
Novo Integrated Sciences GAAP EPS of -$0.12, revenue of $3.42M
May 24, 2023 | finance.yahoo.com
Novo Integrated Sciences Reports Fiscal Year 2023 First Quarter Financial Results
April 27, 2023 | finance.yahoo.com
Novo Integrated Sciences Signs Agreements for an Unsecured, Non-dilutive Debt Instrument with a Principal Sum of $70,000,000
April 3, 2023 | finance.yahoo.com
Novo Integrated Sciences Reports Fiscal Full Year 2022 Financial Results
March 2, 2023 | msn.com
A Look Into Novo Integrated Sciences' Debt
June 5, 2023 | Edge On The Street (Ad)
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
February 23, 2023 | seekingalpha.com
NVOS Novo Integrated Sciences, Inc.
January 17, 2023 | finance.yahoo.com
Novo Integrated Sciences Provides Update on Certain Current Actions and Events
December 21, 2022 | finance.yahoo.com
Novo Integrated Sciences Announces Receipt of Notice from Nasdaq
November 30, 2022 | finance.yahoo.com
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.
November 8, 2022 | finance.yahoo.com
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Smart Healthcare Solution Provider, TiaTech USA Inc.
October 25, 2022 | finance.yahoo.com
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Tranquility Lifestyle Solutions
October 14, 2022 | msn.com
Wall Street Set to Open Higher as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey
October 14, 2022 | benzinga.com
Why Novo Integrated Sciences Stock Is Trading Lower By Over 50%
October 13, 2022 | finance.yahoo.com
Novo Integrated Sciences, Inc. Announces Pricing of $2.0 Million Public Offering
October 13, 2022 | benzinga.com
1NVOS : Novo Integrated Sciences' Subsidiary, Clinical Consultants Int'l,...
October 12, 2022 | finance.yahoo.com
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Services Agreement with Information Technology Company, Softhread
August 29, 2022 | finance.yahoo.com
Novo Integrated Sciences, Inc. (NVOS)
July 14, 2022 | finance.yahoo.com
Novo Integrated Sciences Reports Record Revenue of $13.8 million in Fiscal 2022 Third Quarter
June 23, 2022 | finance.yahoo.com
Novo Integrated Sciences’ Chairman and CEO to Present at the AAPI CEO Forum on the Future of Healthcare: Technology, Transformation and Beyond
June 23, 2022 | benzinga.com
Novotech Receives CRO Leadership Award for Exceeding Customer Expectations
April 26, 2022 | tmcnet.com
Novo Integrated Sciences' Chief Medical Officer, Dr. Joseph M. Chalil, Selected as Top Physician of the Year by IAOTP
April 26, 2022 | finance.yahoo.com
Novo Integrated Sciences’ Chief Medical Officer, Dr. Joseph M. Chalil, Selected as Top Physician of the Year by IAOTP
April 13, 2022 | finance.yahoo.com
Novo Integrated Sciences Reports Fiscal 2022 Second Quarter Financial Results
See More Headlines

NVOS Price History

NVOS Company Calendar

Today
6/05/2023
Next Earnings (Estimated)
7/13/2023
Fiscal Year End
8/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Engines & turbines
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVOS
CUSIP
N/A
CIK
1138978
Web
novointegrated.com
Phone
(206) 617-9797
Fax
N/A
Employees
91
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,850,000.00
Net Margins
N/A
Pretax Margin
-299.28%
Return on Equity
-99.64%
Return on Assets
-60.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.66
Quick Ratio
0.51

Sales & Book Value

Annual Sales
$11.74 million
Price / Sales
1.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.71 per share
Price / Book
0.18

Miscellaneous

Outstanding Shares
144,860,000
Free Float
87,784,000
Market Cap
$18.64 million
Optionable
Not Optionable
Beta
-0.55

Key Executives

  • Robert Mattacchione
    Chairman & Chief Executive Officer
  • Christopher David
    President, Chief Operating Officer & Director
  • James Zsebok
    Chief Financial & Accounting Officer
  • Joseph M. Chalil
    Chief Medical Officer
  • Indrajit Sinha
    Chief Science Officer

Key Competitors

View All Competitors













NVOS Stock - Frequently Asked Questions

How have NVOS shares performed in 2023?

Novo Integrated Sciences' stock was trading at $0.2011 at the beginning of the year. Since then, NVOS shares have decreased by 36.0% and is now trading at $0.1287.
View the best growth stocks for 2023 here.

When is Novo Integrated Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 13th 2023.
View our NVOS earnings forecast.

What is Novo Integrated Sciences' stock symbol?

Novo Integrated Sciences trades on the NASDAQ under the ticker symbol "NVOS."

How do I buy shares of Novo Integrated Sciences?

Shares of NVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Integrated Sciences' stock price today?

One share of NVOS stock can currently be purchased for approximately $0.13.

How much money does Novo Integrated Sciences make?

Novo Integrated Sciences (NASDAQ:NVOS) has a market capitalization of $18.64 million and generates $11.74 million in revenue each year. The company earns $-32,850,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

How can I contact Novo Integrated Sciences?

Novo Integrated Sciences' mailing address is 11120 NE 2ND STREET SUITE 100, BELLEVUE WA, 98004. The official website for the company is novointegrated.com. The company can be reached via phone at (206) 617-9797 or via email at info@novointegrated.com.

This page (NASDAQ:NVOS) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -